CN106214635A - 一种氟尿嘧啶注射液药物组合物 - Google Patents
一种氟尿嘧啶注射液药物组合物 Download PDFInfo
- Publication number
- CN106214635A CN106214635A CN201610827726.1A CN201610827726A CN106214635A CN 106214635 A CN106214635 A CN 106214635A CN 201610827726 A CN201610827726 A CN 201610827726A CN 106214635 A CN106214635 A CN 106214635A
- Authority
- CN
- China
- Prior art keywords
- water
- fluorouracil
- preparation
- pharmaceutical composition
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 13
- 229940081995 fluorouracil injection Drugs 0.000 title description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 51
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims abstract description 35
- 229960002949 fluorouracil Drugs 0.000 claims abstract description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000000203 mixture Substances 0.000 claims abstract description 23
- 235000011121 sodium hydroxide Nutrition 0.000 claims abstract description 18
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims abstract description 16
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 claims abstract description 13
- 229940009662 edetate Drugs 0.000 claims abstract description 11
- 239000002671 adjuvant Substances 0.000 claims abstract description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 20
- 238000002360 preparation method Methods 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 11
- 239000001301 oxygen Substances 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 9
- 230000001954 sterilising effect Effects 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 230000033228 biological regulation Effects 0.000 claims description 6
- 239000003610 charcoal Substances 0.000 claims description 6
- 230000001186 cumulative effect Effects 0.000 claims description 6
- 238000005262 decarbonization Methods 0.000 claims description 6
- 229940105082 medicinal charcoal Drugs 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 230000008901 benefit Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 description 12
- 229940090044 injection Drugs 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000008215 water for injection Substances 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000008354 sodium chloride injection Substances 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000005497 Thymidylate Synthase Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- VSJVHFFAEGLOBH-UHFFFAOYSA-N [F].C1=CN=CN=C1 Chemical compound [F].C1=CN=CN=C1 VSJVHFFAEGLOBH-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001399 anti-metabolic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000000120 body fluid compartment Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000002587 enol group Chemical group 0.000 description 1
- 208000010932 epithelial neoplasm Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002719 pyrimidine nucleotide Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 208000020615 rectal carcinoma Diseases 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种药物组合物,由作为活性成分的氟尿嘧啶和作为辅料的氢氧化钠、依地酸盐和水组成,其特征是每1000ml组合物中氟尿嘧啶含量为20‑30g,氢氧化钠含量为6.0‑8.5g,依地酸盐为依地酸二钠或依地酸钙钠,含量为0.01g,余量为水。
Description
技术领域:
本发明涉及一种由作为活性成分的氟尿嘧啶和作为辅料的氢氧化钠、依地酸盐和水组成药物组合物及其制备方法。
背景技术:
由氟尿嘧啶作为活性成分的注射药物组合物,抗瘤谱较广,通过静脉注射或静脉滴注,主要用于治疗消化道肿瘤,或较大剂量氟尿嘧啶治疗绒毛膜上皮癌。亦常用于治疗乳腺癌、卵巢癌、肺癌、宫颈癌、膀胱癌及皮肤癌等。
氟尿嘧啶是一种水中溶解度低的药物,分子量小,分子中有两个活泼的酰亚胺基,存在烯醇型互变异构。目前,关于氟尿嘧啶的剂型还有很多,如片剂、胶囊及其水溶性注射液等。本品口服吸收不规则,生物利用度低,胃肠道反应较严重,血药浓度达峰时间较长,血药浓度和体液分布不恒定,故临床一般采用静注或静滴给药。
李亚林等人(口服氟尿嘧啶类抗癌药的研究进展,国外医学-合成药,生化药制剂分册2001,22(6),323-326)报道5-氟尿嘧啶(5Fu)属抗代谢类细胞毒性药物,1957 年Dushinsky 等国外学者人工合成了第一代氟化嘧啶类药物,并在临床应用成功,为抗代谢类药物抗肿瘤治疗奠定了基础。5Fu 为细胞周期特异性药物,主要抑制 S 期瘤细胞,在体内先转变为 5-氟-2-脱氧尿嘧啶核苷酸,后者抑制胸腺嘧啶核苷酸合成酶,阻断脱氧尿嘧啶核苷酸转变为脱氧胸腺嘧啶核苷酸,从而抑制 DNA 的生物合成。此外,还能掺入 RNA,通过阻止尿嘧啶和乳清酸掺入 RNA 而达到抑制 RNA 合成的作用。5 氟尿嘧啶主要经肝脏分解代谢,大部分降解为二氧化碳经呼吸道排出体外,约15%在给药 1 小时内经肾以原型药排出体外。大剂量用药能透过血脑屏障,静注后于半小时内到达脑脊液中,并可维持 3小时,T1/2α 为 10~20 分钟,T1/2β 为20 小时。
张建礼等人(氟尿嘧啶氯化钠注射液生产工艺研究,制剂技术,2003年第12卷第8期,41-43页)报道目前已上市的氟尿嘧啶注射液(10ml:0.25g)为小针剂,临床上是将小针剂的氟尿嘧啶用0.9 %氯化钠注射液或 5%葡萄糖注射液稀释后静脉滴注,此过程不但繁琐,而且药液易被污染而引起不良反应。为了保证用药的安全性、有效性和使用方便,笔者研制了大容量注 射剂氟尿嘧啶氯化钠注射液(250ml,氟尿嘧啶0.5g,氯化钠2.25g),可避免二次污染。
CN201310481636.8提供一种注射用氟尿嘧啶组合物冻干粉针,涉及药品及药品制造技术领域,包含以下重量份原料成分:氟尿嘧啶9.26~11.16份,壳聚糖纳米粒4.63~5.58份,注射用水84.35~88.56份。本发明的优点是:本发明氟尿嘧啶组合物以冻干粉针形式存在,溶解性好,比普通的氟尿嘧啶小水针稳定,这种良好的溶解性和稳定性,既保证了用药的安全性,也延长了氟尿嘧啶的有效期。
CN201010204325.3 报道一种氟尿嘧啶口服乳,按照原辅料配比,氟尿嘧啶占口服乳总重量的1~5%,其他辅料占口服乳总重量的20~40%,纯净水占口服乳总重量的60~80%,辅料采用大豆磷脂、植物油、氢氧化钠、聚山梨脂-80、香草香精、糖精钠、橘子香精、羟苯乙脂中的一种或多种。本发明产品质量符合中国药典要求、稳定性好、不会出现分层混浊。
CN200510020320.4 公开了一种氟尿嘧啶注射乳剂,它是按下述重量配比配制成1000毫升注射液:氟尿嘧啶1.0~10.0g、注射用植物油50~300g、和/或多糖类1.0~10.0g、乳化剂5~20g、等渗调节剂20~60g、注射用水加至1000ml,其制备方法包括溶解、加热、混匀、乳化、冷却、灌装、灭菌等工艺步骤;本发明治疗剂量低,毒性反应及刺激性小,疗效高,安全可靠,药效具有持续性、靶向性、缓释性和营养性,该注射乳剂在用于治疗的同时,还能达到供给患者能量的作用,对消化道癌症(如结肠癌、直肠癌、胃癌)、乳腺癌、原发性肝癌等癌症有明显的积极治疗作用。
在文献中从未发现降低氧含量对于稳定性具有一定的影响。
发明内容:
通过长期的试验,我们惊奇的发现,
一种药物组合物,由作为活性成分的氟尿嘧啶和作为辅料的氢氧化钠、依地酸盐和水组成,其特征是每1000ml组合物中氟尿嘧啶含量为20-30g,氢氧化钠含量为6.0-8.5g,依地酸盐为依地酸二钠或依地酸钙钠,含量为0.01g,余量为水。
上述的药物组合物,其特征在于组合物中的氧含量在3mg/L以下。上述的制备方法,其特征是将补加水至全量后再将药液经0.22μm滤芯过滤。上述的制备方法,其特征是灌装后在100~115℃条件下保持30分钟进行灭菌。上述的制备方法,其特征是灌装后在120~125℃条件下保持15分钟进行灭菌。
上述的药物组合物的制备方法,其特征是将组合物总体积50%以上的水放与氟尿嘧啶混合,将氢氧化钠调成10%的溶液后调节上述液体PH值至大于8,全溶后,加入用少量水溶解的依地酸盐,再称取0.3%药用炭加入容器中,搅匀,脱炭过滤,补加水至全量,搅拌均匀,通入氮气后灌装。上述的制备方法,其特征在于通入氮气后使组合物中的氧含量在3mg/L以下。
上述的药物组合物,其特征在于给药途径为通过注射进入体内。
具体实施方式
实施例1
处方:
成分 | 实施例1-1 | 实施例1-2 | 实施例1-3 |
氟尿嘧啶(g) | 200 | 250 | 300 |
氢氧化钠(g) | 60 | 70 | 85 |
依地酸二钠(g) | 0.1 | 0.1 | 0.1 |
注射用水加至(ml) | 10000 | 10000 | 10000 |
氧含量(mg/L) | 2.23 | 1.68 | 2.95 |
制备方法:
将组合物总体积50%以上的水放与氟尿嘧啶混合,将氢氧化钠调成10%的溶液后调节上述液体PH值至大于8,全溶后,加入用少量水溶解的依地酸盐,再称取0.3%药用炭加入容器中,搅匀,脱炭过滤,补加水至全量,搅拌均匀,通入氮气后灌装,使组合物中的氧含量在3mg/L以下后灌装。灌装后在120~125℃条件下保持15分钟进行灭菌。
实施例2
处方:
成分 | 实施例2-1 | 实施例2-2 | 实施例2-3 |
氟尿嘧啶(g) | 200 | 250 | 300 |
氢氧化钠(g) | 60 | 70 | 85 |
依地酸钙钠(g) | 0.1 | 0.1 | 0.1 |
注射用水加至(ml) | 10000 | 10000 | 10000 |
氧含量(mg/L) | 2.12 | 1.36 | 2.87 |
制备方法:
将组合物总体积50%以上的水放与氟尿嘧啶混合,将氢氧化钠调成10%的溶液后调节上述液体PH值至大于8,全溶后,加入用少量水溶解的依地酸盐,再称取0.3%药用炭加入容器中,搅匀,脱炭过滤,补加水至全量,搅拌均匀,通入氮气后灌装,使组合物中的氧含量在3mg/L以下后灌装。灌装后在100~115℃条件下保持30分钟进行灭菌。
对照实施例1
处方:
成分 | 实施例1-1 | 实施例1-2 | 实施例1-3 |
氟尿嘧啶(g) | 200 | 250 | 300 |
氢氧化钠(g) | 60 | 70 | 85 |
依地酸二钠(g) | 0.1 | 0.1 | 0.1 |
注射用水加至(ml) | 10000 | 10000 | 10000 |
氧含量(mg/L) | 4.23 | 3.23 | 7.95 |
制备方法:
将组合物总体积50%以上的水放与氟尿嘧啶混合,将氢氧化钠调成10%的溶液后调节上述液体PH值至大于8,全溶后,加入用少量水溶解的依地酸盐,再称取0.3%药用炭加入容器中,搅匀,脱炭过滤,补加水至全量,搅拌均匀,对照实施例1-1和1-2通入氮气,对照实施例1-3不通入氮气。灌装后在120~125℃条件下保持15分钟进行灭菌。
对照实施例2
处方:
成分 | 实施例2-1 | 实施例2-2 | 实施例2-3 |
氟尿嘧啶(g) | 200 | 250 | 300 |
氢氧化钠(g) | 60 | 70 | 85 |
依地酸钙钠(g) | 0.1 | 0.1 | 0.1 |
注射用水加至(ml) | 10000 | 10000 | 10000 |
氧含量(mg/L) | 4.23 | 3.23 | 7.95 |
制备方法:
将组合物总体积50%以上的水放与氟尿嘧啶混合,将氢氧化钠调成10%的溶液后调节上述液体PH值至大于8,全溶后,加入用少量水溶解的依地酸盐,再称取0.3%药用炭加入容器中,搅匀,脱炭过滤,补加水至全量,搅拌均匀,对照实施例1-1和1-2通入氮气,对照实施例1-3不通入氮气。灌装后在100~115℃条件下保持30分钟进行灭菌。
试验实施例1稳定性对比实验
按照实施例1、2,对照实施例1、2的方法分别制得各20批。随机将每10批分为1组,分别进行高温、光照实验,目测观察实验结果。
1.1高温实验:
将样品分别于60 ℃恒温干燥箱中放置90天,观察样品颜色和透明度,结果如下。
1.2光照实验:
将样品分别于60 ℃恒温干燥箱中放置30天,光照射30d (强度3 000lx) ,观察样品颜色和透明度,结果如下。
。
Claims (8)
1.一种药物组合物,由作为活性成分的氟尿嘧啶和作为辅料的氢氧化钠、依地酸盐和水组成,其特征是每1000ml组合物中氟尿嘧啶含量为20-30g,氢氧化钠含量为6.0-8.5g,依地酸盐为依地酸二钠或依地酸钙钠,含量为0.01g,余量为水。
2.如权利要求1所述的药物组合物,其特征在于组合物中的氧含量在3mg/L以下。
3.一种权利要求1所述的药物组合物的制备方法,其特征是将组合物总体积50%以上的水放与氟尿嘧啶混合,将氢氧化钠调成10%的溶液后调节上述液体PH值至大于8,全溶后,加入用少量水溶解的依地酸盐,再称取0.3%药用炭加入容器中,搅匀,脱炭过滤,补加水至全量,搅拌均匀,通入氮气后灌装。
4.一种权利要求2所述的制备方法,其特征是将补加水至全量后再将药液经0.22μm滤芯过滤。
5.一种权利要求2所述的制备方法,其特征是灌装后在100~115℃条件下保持30分钟进行灭菌。
6.一种权利要求2所述的制备方法,其特征是灌装后在120~125℃条件下保持15分钟进行灭菌。
7.如权利要求3所述的制备方法,其特征在于通入氮气后使组合物中的氧含量在3mg/L以下。
8.一种权利要求1所述的药物组合物,其特征在于给药途径为通过注射进入体内。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610827726.1A CN106214635B (zh) | 2016-09-18 | 2016-09-18 | 一种氟尿嘧啶注射液药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610827726.1A CN106214635B (zh) | 2016-09-18 | 2016-09-18 | 一种氟尿嘧啶注射液药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106214635A true CN106214635A (zh) | 2016-12-14 |
CN106214635B CN106214635B (zh) | 2019-05-10 |
Family
ID=58075569
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610827726.1A Active CN106214635B (zh) | 2016-09-18 | 2016-09-18 | 一种氟尿嘧啶注射液药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106214635B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109568276A (zh) * | 2019-01-23 | 2019-04-05 | 海南卓泰制药有限公司 | 一种注射用氟尿嘧啶冻干剂及其制备方法 |
CN110898001A (zh) * | 2019-11-05 | 2020-03-24 | 黑龙江福和制药集团股份有限公司 | 一种耐低温的5-氟尿嘧啶注射液 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103536551A (zh) * | 2013-10-15 | 2014-01-29 | 海南卫康制药(潜山)有限公司 | 注射用氟尿嘧啶组合物冻干粉针 |
WO2014025807A1 (en) * | 2012-08-06 | 2014-02-13 | Spectrum Pharmaceuticals, Inc. | Pharmaceutical compositions comprising l-leucovorin |
-
2016
- 2016-09-18 CN CN201610827726.1A patent/CN106214635B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014025807A1 (en) * | 2012-08-06 | 2014-02-13 | Spectrum Pharmaceuticals, Inc. | Pharmaceutical compositions comprising l-leucovorin |
CN103536551A (zh) * | 2013-10-15 | 2014-01-29 | 海南卫康制药(潜山)有限公司 | 注射用氟尿嘧啶组合物冻干粉针 |
Non-Patent Citations (7)
Title |
---|
LAWRENCE A.TRISSEL: "《药品注射剂使用指南》", 30 November 2005, 上海科学技术出版社 * |
ZHANG31505: "氟尿嘧啶注射液说明书", 《百度文库》 * |
周瑾,等: "两种方法分析氟尿嘧啶在高氧液中的稳定性", 《华西药学杂志》 * |
国家药典委员会: "《中华人民共和国药典 第四部》", 30 June 2015, 中国医药科技出版社 * |
姚静: "《药用辅料应用指南》", 31 August 2011, 中国医药科技出版社 * |
李大魁: "《现代临床药物手册》", 31 January 1993, 中国医药科技出版社 * |
李威,等: "《药剂学》", 28 February 2014, 湖北科学技术出版社 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109568276A (zh) * | 2019-01-23 | 2019-04-05 | 海南卓泰制药有限公司 | 一种注射用氟尿嘧啶冻干剂及其制备方法 |
CN110898001A (zh) * | 2019-11-05 | 2020-03-24 | 黑龙江福和制药集团股份有限公司 | 一种耐低温的5-氟尿嘧啶注射液 |
Also Published As
Publication number | Publication date |
---|---|
CN106214635B (zh) | 2019-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105616361A (zh) | 一种注射用替尼类药物白蛋白纳米制剂的制备方法 | |
CN100375621C (zh) | 长春瑞滨脂质微球注射液及其制备方法 | |
CN102397547B (zh) | 一种抗癌药物组合物 | |
CN107812008A (zh) | 一种近红外荧光成像小分子抗癌纳米药物的制备方法 | |
CN106214635B (zh) | 一种氟尿嘧啶注射液药物组合物 | |
CN109718228A (zh) | 米托蒽醌的抗肿瘤淋巴转移作用及其药物制剂 | |
CN101007003A (zh) | 一种稳定的托拉塞米注射液及其制备方法 | |
CN101953775B (zh) | 用做可注射皮下植入剂的纳米粒水凝胶 | |
CN105456200A (zh) | 一种提高难溶性药物口服生物利用度的纳米粒微球的制备方法及应用 | |
CN102068435A (zh) | 一种复方氟尿嘧啶抗肿瘤药 | |
Ike et al. | Treatment of malignant pleural effusions with doxorubicin hydrochloride-containing poly (L-lactic acid) microspheres | |
CN102697732A (zh) | 一种基因和疏水药物共负载peg化纳米粒子的制备方法 | |
CN100526324C (zh) | 制备反式-或顺式-二铵二氯二羟合铂(ⅳ)的方法及其用于制备药物有效物质的用途 | |
CN1225242C (zh) | 一种抗肿瘤药物毛兰素脂肪乳剂及其制备方法 | |
CN102309491B (zh) | 一种替加氟、吉美斯特复方注射液 | |
CN102526714B (zh) | 治疗肿瘤的药物组合物及其制备方法 | |
CN102727867B (zh) | 一种抗肿瘤用药物组合物及应用、试剂盒及包装件 | |
CN100377712C (zh) | 葫芦素脂质体组方及其制剂 | |
CN102579419B (zh) | 绿原酸的抗癌用途 | |
CN105232465A (zh) | 一种芬苯达唑脂质体制剂及其制备方法 | |
CN102125558A (zh) | 一种复方左亚叶酸钠氟尿嘧啶抗肿瘤药 | |
CN1867344A (zh) | 含有氧代铂、其盐和衍生物的药物组合物 | |
CN106074398A (zh) | 一种香菇多糖冻干粉针剂及其制备方法 | |
CN102716465B (zh) | 治疗肿瘤的药物组合物及其制备方法 | |
CN101984961B (zh) | 含蓬莪术环二烯的药物组合物、其制剂制备工艺及其医药用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: No. 221, Huanghai Road, Binhai New Area, Tianjin 300457 Patentee after: Tianjin Pharmaceutical Heping (Tianjin) Pharmaceutical Co.,Ltd. Country or region after: China Address before: No. 221, Huanghai Road, Binhai New Area, Tianjin 300457 Patentee before: TIANJIN KINGYORK PHARMACEUTICAL CO.,LTD. Country or region before: China |